Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
Somatic mutations in the kinase domain of the epidermal growth factor receptor tyrosine kinase gene EGFR are common in lung adenocarcinoma. The presence of mutations correlates with tumor sensitivity to the EGFR inhibitors erlotinib and gefitinib, but the transforming potential of specific mutations...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2005-11-01
|
Series: | PLoS Medicine |
Online Access: | http://europepmc.org/articles/PMC1240052?pdf=render |